Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has reported that Lyrica, approved for the management of fibromyalgia, has reduced pain in fibromyalgia patients regardless of whether they experienced symptoms of anxiety or depression at the beginning of the study.
Subscribe to our email newsletter
The results are from a retrospective, pooled analysis of data from three placebo-controlled clinical trials (eight weeks, 13 weeks and 14 weeks long) of Lyrica in over 2,000 fibromyalgia patients. In the studies, 38% of fibromyalgia patients had moderate to severe anxiety symptoms, while 27% had moderate to severe depressive symptoms. These studies randomized patients to receive Lyrica 150mg, 300mg, 450mg or 600mg or placebo.
The new analysis confirmed that Lyrica was significantly more effective than placebo in reducing pain in patients with fibromyalgia. Patients receiving 600mg a day of Lyrica had a pain reduction of 2.08 on the pain scale; 450mg a day had a reduction of 2.01; 300mg a day had a reduction of 1.76; 150mg a day had a reduction of 1.37, and placebo had a reduction of 1.25. Additionally, Lyrica was found to reduce pain in patients regardless of whether they had symptoms of anxiety or depression.
The analysis also examined the relationship between improvements in pain, sleep, fatigue, anxiety and depressive symptoms with patients reporting feeling ‘much improved’ or ‘very much improved’ as measured by the Patient Global Impression of Change (PGIC).